These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 4196905)

  • 1. Triple massive-dose drug therapy in combined treatment of advanced ovarian carcinoma.
    Vahrson H
    Geburtshilfe Frauenheilkd; 1973 Apr; 33(4):293-6. PubMed ID: 4196905
    [No Abstract]   [Full Text] [Related]  

  • 2. [Proceedings: Triple-drug massive therapy in advanced ovarian carcinoma].
    Vahrson H
    Arch Gynakol; 1973 Sep; 214(1):391-4. PubMed ID: 4801493
    [No Abstract]   [Full Text] [Related]  

  • 3. [Combined therapy of ovarian cancer (author's transl].
    Vahrson H; Wolf A; Jankowski R
    Geburtshilfe Frauenheilkd; 1977 Feb; 37(2):131-8. PubMed ID: 838261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of 126 cases of advanced ovarian carcinoma with cyclophosphamide.
    Beck RE; Boyes DA
    Can Med Assoc J; 1968 Mar; 98(11):539-41. PubMed ID: 5647240
    [No Abstract]   [Full Text] [Related]  

  • 5. [Results of a cyclophosphamide therapy in genital and mammary carcinomas].
    Naumann R
    Zentralbl Gynakol; 1970 May; 92(22):700-2. PubMed ID: 5284155
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of advanced ovarian carcinoma with a combination of hexmethylmelamine, cyclophosphamide, methotrexate, and 5-fluorourcil (hexa-CAF) in patients with and without previous treatment.
    Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
    Cancer Treat Rep; 1980; 64(2-3):323-6. PubMed ID: 6773656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Surgical method and combination chemotherapy in treating stage-III and IV ovarian cancer].
    Grigorova TM; Vartanian LG; Marenich AF
    Vopr Onkol; 1980; 26(2):81-5. PubMed ID: 6767311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of advanced ovarian cancer].
    de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
    Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A randomized clinical trial of cyclophosphamide versus adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate in advanced ovarian carcinoma--a preliminary report ].
    Chylak V; Ilijas M; Krusić J; Kolarić K
    Lijec Vjesn; 1982; 104(3-4):120-2. PubMed ID: 6750298
    [No Abstract]   [Full Text] [Related]  

  • 10. [Advanced epithelial cancers of the ovary: results of 4 chemotherapy protocols (110 cases)].
    Israël L; Lepage E; Breau JL; Aguilera J
    Bull Cancer; 1982; 69(5):426-33. PubMed ID: 6891902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
    Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D
    Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytoprotective effect of Amifostine in the combined chemotherapy of advanced ovarian carcinoma].
    Nagy P; Kádasi L
    Orv Hetil; 2000 Sep; 141(37):2027-30. PubMed ID: 11037611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic trial of a combination of cytostatic agents in advanced ovarian carcinoma].
    Brandl K
    Zentralbl Gynakol; 1970 Feb; 92(8):233-9. PubMed ID: 5505972
    [No Abstract]   [Full Text] [Related]  

  • 15. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
    Samaritani R; Corrado G; Vizza E; Sbiroli C
    BMC Cancer; 2007 Apr; 7():65. PubMed ID: 17433113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer.
    Mangioni C; Bolis G; Natale N; Morasca L
    Eur J Cancer (1965); 1976 May; 12(5):353-6. PubMed ID: 954793
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of ovarian cancer in the Hospital for Women of the Medical Academy in Dresden and its results].
    Schreiber H; Schneck P
    Z Arztl Fortbild (Jena); 1969 Feb; 63(3):167-70. PubMed ID: 5785468
    [No Abstract]   [Full Text] [Related]  

  • 20. [Massive dose cyclophosphamide treatment in combination with radiotherapy in patients with advanced cancer].
    Blumenberg FW; Scheef W
    Med Welt; 1969 Sep; 37():2024-9. PubMed ID: 5389268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.